Topics

Experts Explain Impact of Trastuzumab Deruxtecan Approval in HER2+ Breast Cancer

14:32 EDT 26 Mar 2020 | OncLive

Faculty voice their opinion on the clinical utility of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer.

Original Article: Experts Explain Impact of Trastuzumab Deruxtecan Approval in HER2+ Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Experts Explain Impact of Trastuzumab Deruxtecan Approval in HER2+ Breast Cancer"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...